Investment and Company Research
Opportunity Research
HOT TOPICS

June 12, 2013

Nuvilex is Beneficiary of Doctors’ Approach Toward Medical Marijuana

Earlier this year, Nuvilex, Inc. (OTCQB – NVLX  - $0.1257 – Spec Buy) announced that it was entering the medical marijuana research and product development arena to much fanfare.  Most national polls have demonstrated that the majority of Americans appear to be in favor of medical marijuana programs, in some way shape or form. To that end, already 19 states and the District of Columbia have approved some sort of medical marijuana programs, despite no change in stance by the federal government.

While it is widely believed that the government’s sentiment will change over time, what may be the key driver to the success of clinical marijuana treatment initiatives and programs are strong support and a real desire for the introduction of new therapies by the medical community itself.  A recent poll published in the May 30, 2013 edition of The New England Journal of Medicine shows that fully 76% of poll participants (the poll results include some doctors from outside the U.S) are in favor of the use of marijuana for medicinal purposes. Interestingly, only 1% of the voters in Utah supported the notion while 96% of the voters in Pennsylvania were in favor.    

This amazing figure bodes extremely well for companies like Nuvilex. Interestingly, while much of the attention regarding medical marijuana development and research has centered on pain management, appetite, and mood, etc., this poll, much as Nuvilex’s emphasis will be, was focused on cancer treatment.  In the poll, doctors surveyed were given a hypothetical case about a woman named "Marilyn" a 68-year-old woman with breast cancer that had metastasized and were asked if they would give her medical marijuana to help her with her symptoms.

As noted above over three-fourths of those surveyed in the poll answered in the affirmative. Therefore, it can be assumed that as Nuvilex enters into comprehensive studies on the possible use of cannabidiol (or CBD, which, like THC, is one of the components of Cannabis collectively known as cannabinoids) as the basis for developing treatments for deadly forms of cancer, the Company should have no shortage of supporters from potential subjects and more importantly, from the medical community.  Many prospective patients and their doctors clearly wish to see these alternative forms of treatment studied further and broadly used as real therapies.

For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. 

Disclaimer
 This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.